CYP2C19 and acute coronary syndrome: Testing for CYP2C19 metabolizer status prior to clopidogrel commencement for acute coronary syndrome patients, is supported by the American Heart Association and demonstrated to significantly decrease the risk of recurrent myocardial infarction [74,75,76].